PIPE-791

Phase 2Small molecule

CContineum Therapeutics

PIPE-791 is one of 67 small molecule programs targeting Idiopathic Pulmonary Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic Pulmonary FibrosisActive, not recruiting

OsteoarthritisActive, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

OsteoarthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 2

Ilaris

Novartis

Preclinical

2 3

Toradol

Roche

Preclinical

1 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

PIPE-791

CContineum Therapeutics

Phase 2

1 6

Catapres

Boehringer Ingelheim

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Paracetamol

GSK

Preclinical

4 9

Chirocaine

PPurdue Pharma LP

Preclinical

1 10

Lunesta

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Idiopathic Pulmonary Fibrosis

NCT07284459

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

Completed·CContineum Therapeutics·Phase 1·NCT06810245·43 enrolled

IPF1 trial

PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF

Completed·CContineum Therapeutics·Phase 1·NCT06683612·16 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting·CContineum Therapeutics·Phase 2·NCT07284459·324 enrolled

Unspecified1 trial

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Completed·CContineum Therapeutics·Phase 1·NCT05983939·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PIPE-791. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PIPE-791 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PIPE-791. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Contineum Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CContineum Therapeutics

PIPE-791

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Osteoarthritis1 trial

IPF1 trial

Idiopathic Pulmonary Fibrosis1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News